NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
May 11, 2026 — Oregen Energy appoints Philip Birch as strategic advisor for Namibia's Block 2812Ab, adjacent to the Venus discovery in the Orange Basin. Learn about the company's exploration strategy.
May 11, 2026 — Oregen Energy appoints Philip Birch, geoscientist behind the Venus discovery, as strategic advisor for Namibia's Orange Basin Block 2812Ab. Learn how this expert hire could boost exploration.
May 11, 2026 — Oregen Energy appoints Philip Birch as strategic advisor for Namibia's offshore Block 2812Ab in the Orange Basin, adjacent to the Venus discovery. Birch's expertise boosts exploration strategy. Read more.
May 11, 2026 — inCruises reports record Wave Season with 50,000+ passengers and 20,000+ cruise bookings across 560 itineraries on 12 lines. Global membership from 98 countries drives growth.
May 11, 2026 — K9 bed bug detection achieves 98% accuracy in NY/NJ/CT, outperforming visual inspections. Tristate Bedbug Dogs releases 2026 guide after 1,200 inspections. Learn about certified canine inspection benefits.
May 11, 2026 — Wire Orthodontics expands braces and Invisalign services in Spokane and Liberty Lake, offering personalized care for all ages with direct oversight from Dr. Clint Wire.
May 11, 2026 — Wire Orthodontics expands Liberty Lake capacity, offering braces and Invisalign for all ages. Dr. Clint Wire provides personalized orthodontic care in Liberty Lake WA. Schedule a consultation today.
May 11, 2026 — Twin Vee PowerCats (NASDAQ: VEEE) reports Q1 2026 revenue up 10% YoY, net loss widens, but cash grows. Learn about Bahama Boat Works relaunch and financial results.
May 11, 2026 — Ev0-Tech founder Dan Vega addresses SMB cybersecurity gap after Cyber Defense Magazine feature. Learn about managed IT services San Antonio and security for small businesses.
May 11, 2026 — Search Atlas launches Atlas Agent, an AI system that autonomously executes digital marketing across SEO, social, and paid media, introducing Domain Power and LLM Visibility metrics for generative search.
May 11, 2026 — Footminders survey reveals 53% of standing workers experience frequent foot pain, yet only 22% use orthotic insoles. Learn about the impact on workplace wellness and quality of life.
May 11, 2026 — SureNano Science initiates IND-enabling program for GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes, positioning against Ozempic and Mounjaro in the $200B GLP-1 market.
May 11, 2026 — Springs Rejuvenation expands to Atlanta, offering stem cell exosome therapy, advanced FUE, and joint pain treatments. Fifth clinic nationwide and first in Southeast to offer complete Stem 3 Protocol.
May 11, 2026 — Learn how to choose the best oral rinse for your needs with ioTech International's expert guide. Discover therapeutic rinses that support oral microbiome and gum health, and see how ioRinse Ultra outperforms others.
May 11, 2026 — MindBio Therapeutics unveils AI-powered fatigue detection via voice analysis for high-risk industries. Learn how the technology integrates into Edge AI Kiosks to enhance workplace safety.
May 11, 2026 — HeartBeam pilot study evaluates on-demand 12-lead ECG patch for coronary artery disease detection at two Belgrade hospitals. Learn about the technology and market impact.
May 11, 2026 — Oncotelic Therapeutics (OTLC) advances pipeline without dilution via partnerships, $249M GMP Bio joint venture boost, and AI-driven PDAOAI platform with 28M abstracts. Read the corporate update.
May 11, 2026 — SPARC AI (CSE: SPAI) develops software-only Overwatch platform for GPS-denied drone navigation and targeting, addressing modern warfare needs for scalable autonomous systems.
May 11, 2026 — SureNano Science (SURNF) advances GEP-44, a triple agonist peptide for obesity, in a $200B market. Differentiated with improved tolerability and delivery flexibility, it competes with Eli Lilly, Novo Nordisk.
May 11, 2026 — SureNano Science advances next-gen GLP-1 therapy GEP-44 for obesity and diabetes. Triple agonist peptide targets improved efficacy and tolerability in a booming market led by Eli Lilly and Novo Nordisk.